Adamas Announces New Employment Inducement Grant
December 09 2019 - 4:50PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted four new employees the option to purchase an aggregate of
89,000 shares of the company’s common stock, at a per share
exercise price of $6.48, the closing trading price on December 6,
and restricted stock units to acquire 44,500 shares of the
company’s common stock. The stock options and restricted stock
units vest over four years and were granted pursuant to the Adamas
Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by
the company's board of directors in March 2016 under Rule
5653(c)(4) of the Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the company.
About Adamas Pharmaceuticals,
Inc.Adamas’ goal is to create and commercialize a new
generation of medicines intended to lessen the burden of chronic
neurologic diseases on patients, caregivers and society using its
deep understanding of time-dependent biology. The Company is
focused on the commercialization of GOCOVRI® (amantadine) extended
release capsules, the first and only FDA-approved medicine for the
treatment of dyskinesia in patients with Parkinson’s disease
receiving levodopa-based therapy, with or without concomitant
dopaminergic medications. The Company also continues to deliver
differentiated investigational programs, including ADS-5102 in
development for the treatment of walking impairment in patients
with multiple sclerosis. For more information about Adamas and its
unique approach to developing medicines based on time-dependent
biology, please visit www.adamaspharma.com.
Contact:
Investors:Peter VozzoWestwicke Partners
443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Communications &
Engagement 510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024